Change in Ratings
American International Group(AIG Quote) upgraded at B of A to Buy from Neutral. $35 price target. The risk/reward for AIG has become very attractive based upon the de-leveraging, risk reduction and simplification of the company.
Biogen(BIIB Quote) upgraded at Merrill Lynch to Buy from Underperform. $64-$79 price target. Upgrade is based upon earning growth potential, improved outlook for the multiple sclerosis market and a diverse mid-late stage pipeline.
Cintas(CTAS Quote) upgraded at Morgan Stanley to Equal-weight. $29 price target. CTAS has turned in very respectable F4Q08 performance in light of the weak economy, fierce competition and high energy prices. The stock is down 20% on the year and the risk/reward within the stock is now more balanced leading to the Equal-weight rating. ...
Recent Comments
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 10,308.26 | 1,096.07 | 2,180.05 | 34.87 |
Oil *
73.22
|
|
DOWN
132.86
|
DOWN
13.11
|
DOWN
26.86
|
DOWN
1.09
|
10 Yr
3.49%
SPDR Gold
107.34
|
|
-1.27%
|
-1.18%
|
-1.22%
|
-3.03%
|
Data delayed 20 minutes |
Connect with TheStreet